Filgrastim | compare suppliers & send inquiries for free
Apino Pharma Co., Ltd. MOQ: 1 g Type: Producer Origin: China | |||
Intas Pharma Type: Producer Origin: United Kingdom | |||
Hangzhou Jiuyuan Gene Engineering Type: Producer Origin: China |
Looking for Filgrastim 121181-53-1?
- API | Excipient name:
- Filgrastim
- Synonyms:
- G-CSF, Tbo-filgrastim
- Cas Number:
- 121181-53-1
- DrugBank number:
- DB00099
- Unique Ingredient Identifier:
- PVI5M0M1GW
About Filgrastim
More information about this product: Chemotherapy-induced neutropenia (CIN) is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality and can increase the cost of cancer therapy. In these cases, colony stimulating factor is necessary to restore important cells for immune function For over twenty years, granulocyte colony-stimulating factors (G-CSFs; filgrastims) have been a pillar of treatment and prevention of CIN, and have been found to reduce the risk of neutropenia across various patient settings, decrease the incidence of febrile neutropenia, reduce the incidence of infection, reduce the requirement for treatment with antibiotics, and accelerate neutrophil recovery.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.
Filgrastim manufacturers | traders | suppliers
We have 3 companies offering Filgrastim from 2 different countries.
Get in contact with the supplier of your choice:
- Apino Pharma Co., Ltd. from China
- Hangzhou Jiuyuan Gene Engineering from China
- Intas Pharma from United Kingdom
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.